Open-label trial of paroxetine in children with obsessive-compulsive disorder

Authors
Citation
Rs. Diler et A. Avci, Open-label trial of paroxetine in children with obsessive-compulsive disorder, CURR THER R, 61(10), 2000, pp. 706-719
Citations number
28
Categorie Soggetti
Pharmacology,"Pharmacology & Toxicology
Journal title
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
ISSN journal
0011393X → ACNP
Volume
61
Issue
10
Year of publication
2000
Pages
706 - 719
Database
ISI
SICI code
0011-393X(200010)61:10<706:OTOPIC>2.0.ZU;2-1
Abstract
Objective: The aim of this study was to assess the safety and effectiveness of paroxetine in a group of pediatric patients with obsessive-compulsive d isorder (OCD) who had not previously been treated for that condition. Methods: In a 12-week, open-label study, 47 children (aged 9 to 15 years)we re given a fixed dosage of paroxetine 20 mg/d for 6 weeks. During the next 6 weeks the treating psychiatrist could maintain or change the dosage based on therapeutic effectiveness or side effects. No additional medication was used. Scores on the Clinical Global Impressions-Severity of Illness (CGI-S I) scale, Maudsley Obsessive Compulsive Inventory (MOCI), Children's Depres sion Inventory (CDI), and Spielberger's State-Trait Anxiety Inventory for C hildren (SAI-C and TAI-C), were used to assess efficacy. Adverse effects we re assessed by the Adverse Experience Scale and the CGI-Adverse Effect scor e. Results: The mean paroxetine dosage was 20.7 mg/d. Five patients dropped ou t of the study at week 6; 42 of 47 patients completed the trial and were as sessed. At the end of 6 weeks the children were found to have significantly lower scores on MOCI (total) and the MOCI dirt, doubt, control, and slowne ss subscales and on the CGI-SI scale, CDI, SAI-C, and TAI-C. Twenty-six pat ients showed less than or equal to 50% improvement according to the MOCI. A t the end of the study 12 children were classified as normal, 14 as borderl ine, and 11 as mild on the CGI-SI scale; all the patients were classified a s moderate to most severe at baseline. The mean reduction in the CGI-SI sco re was 56.8% +/- 19.4%. No patient experienced side effects severe enough t o discontinue the drug. Sleepiness (23.4%,), increase in anger (8.5%), fati gue (8.5%), behavioral disinhibition (4.3%), gastrointestinal distress (4.3 %), and increase in preexisting ties (4.3%) were the most common side effec ts. Conclusions: Paroxetine was effective in the treatment of OCD in this sampl e of Turkish children, and the incidence of adverse events was low.